Lorazepam + AZD7325 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recreational CNS Depressant Use
Conditions
Recreational CNS Depressant Use
Trial Timeline
May 1, 2009 → Sep 1, 2009
NCT ID
NCT00902772About Lorazepam + AZD7325 + Placebo
Lorazepam + AZD7325 + Placebo is a phase 1 stage product being developed by AstraZeneca for Recreational CNS Depressant Use. The current trial status is completed. This product is registered under clinical trial identifier NCT00902772. Target conditions include Recreational CNS Depressant Use.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00902772 | Phase 1 | Completed |
Competing Products
4 competing products in Recreational CNS Depressant Use
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lasmiditan + Alprazolam + Placebo | Eli Lilly | Phase 1 | 33 |
| ACT-541468 + Suvorexant + Zolpidem + Placebo | Idorsia | Phase 1 | 28 |
| PF614 + Oxycodone | Ensysce Biosciences | Phase 1 | 25 |
| PF614 + Oxycodone Hydrochloride 40 mg + Placebo | Ensysce Biosciences | Phase 1 | 25 |